Related Experiment Video
Updated: Aug 12, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
Silent myocardial ischaemia in treated hypertensives with and without left ventricular hypertrophy
Milos M Stojanovic1, Eoin O'Brien, Simon Lyons
1Blood Pressure Unit and ADAPT Centre, Beaumont Hospital, Dublin 9, Ireland.
Insights
Hypertensive patients with left ventricular hypertrophy (LVH) show a significantly higher prevalence of silent ischaemia compared to those without LVH. Ambulatory ECG monitoring can help identify high-risk patients for cardiovascular complications.
Area of Science:
- Cardiology
- Hypertension Research
- Ischaemia Studies
Background:
- Silent ischaemia increases risk for myocardial infarction and sudden death.
- Left ventricular hypertrophy (LVH) is common in hypertensive patients.
- Prevalence of silent ischaemia in hypertensive patients with and without LVH requires examination.
Purpose of the Study:
- To investigate the prevalence of silent ischaemia in hypertensive patients.
- To compare silent ischaemia in hypertensive patients with and without LVH.
Main Methods:
- 24-h ambulatory blood pressure and ECG monitoring used.
- Included 20 hypertensive patients with LVH and 20 matched controls without LVH.
- Ischaemic events defined by asymptomatic ST-depression criteria.
Main Results:
- 13/20 patients with LVH experienced ischaemic events vs. 4/20 without LVH.
- Median ischaemic events were significantly higher in the LVH group (7 vs. 0).
- Median total ischaemic area was significantly greater in hypertensive patients with LVH.
Conclusions:
- Silent ischaemia prevalence is markedly increased in hypertensive patients with LVH.
- Ambulatory ECG monitoring aids in identifying high-risk hypertensive patients.
- LVH indicates increased risk for cardiovascular complications and sudden death.
Background:
Silent ischaemia has been reported to be associated with an increased risk of myocardial infarction and sudden death in a wide range of patient groups. The aim of this study was to examine the prevalence of silent ischaemia in hypertensive patients with and without left ventricular hypertrophy (LVH).
Methods:
Twenty hypertensive patients participating in the Anglo-Scandinavian Cardiac Outcomes Trial with echocardiographic LVH (11 males, nine females), and 20 age, sex, blood pressure, and drug treatment-matched hypertensive patients without LVH underwent 24-h combined ambulatory blood pressure and electrocardiographic (ECG) monitoring. Ischaemic events were defined by the 'rule of 3 x 1'-asymptomatic ST-depression >/= 1 mm (0.1 mV), lasting at least 1 min, and with a duration of at least 1 min between two events.
Results:
Thirteen patients with LVH had ischaemic events, whilst only four without LVH demonstrated ischaemia. Median numbers of events (seven versus zero; P < 0.01) and median total ischaemic area (0.25 versus 0 mV*min/day; P < 0.01) were significantly increased amongst hypertensive patients with LVH by comparison to those without LVH.
Conclusion:
Despite similar levels of established risk factors for atherosclerotic coronary artery disease, the prevalence of silent ischaemia was markedly increased amongst hypertensive patients with LVH by comparison to those with normal left ventricular dimensions. Ambulatory ECG monitoring may have a use in the identification of those at greatest risk of cardiovascular complications and sudden death, amongst hypertensive patients with persistent cardiac hypertrophy despite anti-hypertensive therapy.
More Related Videos
08:38Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery
Published on: August 16, 2019
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Mitral Stenosis I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Myocarditis III: Medical Management
Angina II: Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care